RedHill Biopharma (RDHL) Common Equity (2011 - 2025)

RedHill Biopharma (RDHL) has reported Common Equity for 15 consecutive years, with $4.3 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Common Equity rose 191.14% year-over-year to $4.3 million in Q4 2025; TTM through Dec 2025 was $4.3 million, a 191.14% increase from a year earlier, with the FY2025 full-year figure at $4.3 million, up 191.14% from the prior year.
• Common Equity was $4.3 million for Q4 2025 at RedHill Biopharma, up from -$4.4 million in the prior quarter.
• Over five years, Common Equity peaked at $53.0 million in Q1 2021 and troughed at -$48.4 million in Q4 2022.
• A 5-year average of -$798642.9 and a median of $1.1 million in 2023 frame the typical range for Common Equity.
• The widest YoY moves for Common Equity: up 191.14% in 2025, down 7332.79% in 2025.
• Over 5 years, Common Equity stood at $8.9 million in 2021, then sank by 645.35% to -$48.4 million in 2022, then soared by 104.27% to $2.1 million in 2023, then slumped by 326.34% to -$4.7 million in 2024, then soared by 191.14% to $4.3 million in 2025.
• The last three Common Equity figures came in at $4.3 million (Q4 2025), -$4.4 million (Q2 2025), and -$4.7 million (Q4 2024), per Business Quant data.